Apac Pulmonary Stents Market Report Size, Share, Growth Drivers, Trends, Opportunities & Forecast 2025–2030

APAC Pulmonary Stents Market Overview

• The APAC Pulmonary Stents Market is valued at approximatelyUSD 49 million, based on a five-year historical analysis. This growth is primarily driven by the increasing prevalence of respiratory diseases such as chronic obstructive pulmonary disease (COPD), lung cancer, and asthma, as well as advancements in stent technology and rising healthcare expenditure across the region. The demand for innovative stenting solutions is further fueled by the aging population, heightened exposure to air pollution, and the growing awareness of minimally invasive procedures among healthcare providers and patients.
• Key players in this market includeChina, Japan, and India, which dominate due to their large patient populations, robust healthcare infrastructure, and significant investments in medical technology. China leads with its rapid urbanization and increasing healthcare access, while Japan benefits from advanced medical research and development. India’s growing healthcare sector and rising disposable incomes also contribute to its market prominence.
• In 2017, the Indian government implemented theNational Health Policy, 2017issued by the Ministry of Health and Family Welfare, which emphasizes the importance of affordable healthcare and the integration of advanced medical technologies, including pulmonary stents. This policy aims to enhance access to quality healthcare services and promote innovation in medical devices, thereby supporting the growth of the pulmonary stents market. The policy mandates increased investment in health technology assessment, encourages adoption of innovative medical devices, and sets operational targets for expanding access to advanced interventions.

APAC Pulmonary Stents Market Segmentation

By Type:The market is segmented into various types of stents, including self-expandable stents, balloon-expandable stents, non-expandable/customized 3D-printed stents, drug-eluting stents, bare-metal stents, biodegradable stents, and others. Among these,drug-eluting stentsare gaining traction due to their ability to reduce the risk of restenosis and improve patient outcomes. The increasing adoption of these stents in clinical practice is driven by their effectiveness in treating complex pulmonary conditions, while self-expandable and balloon-expandable stents remain widely used for airway management. Recent trends highlight growing interest in biodegradable and customized 3D-printed stents for patient-specific applications.

By End-User:The end-user segmentation includes hospitals, ambulatory surgical centers, specialty clinics, and others.Hospitalsare the leading end-users of pulmonary stents, primarily due to their comprehensive facilities, specialized medical staff, and the ability to manage complex respiratory cases. The increasing number of hospital admissions for respiratory diseases and the availability of advanced medical technologies in hospitals further drive the demand for pulmonary stents in this segment. Ambulatory surgical centers and specialty clinics are also expanding their role, especially in urban centers, due to the shift toward outpatient and minimally invasive procedures.

APAC Pulmonary Stents Market Competitive Landscape

The APAC Pulmonary Stents Market is characterized by a dynamic mix of regional and international players. Leading participants such as Boston Scientific Corporation, Medtronic plc, Abbott Laboratories, B. Braun Melsungen AG, Cook Medical LLC, Terumo Corporation, Johnson & Johnson (Ethicon), Olympus Corporation, Merit Medical Systems, Inc., Stryker Corporation, CONMED Corporation, Halyard Health, Inc., Micro-Tech (Nanjing) Co., Ltd., Taewoong Medical Co., Ltd., Endo-Flex GmbH contribute to innovation, geographic expansion, and service delivery in this space.

APAC Pulmonary Stents Market Industry Analysis

Growth Drivers

• Increasing Prevalence of Respiratory Diseases:The APAC region is witnessing a significant rise in respiratory diseases, with the World Health Organization reporting that over 300 million people suffer from asthma and 210 million from chronic obstructive pulmonary disease (COPD) globally. In future, the total healthcare expenditure in APAC is projected to reach approximately $1.7 trillion, reflecting a growing need for effective treatment options, including pulmonary stents, to manage these conditions effectively.
• Advancements in Stent Technology:Technological innovations in stent design and materials are enhancing the efficacy and safety of pulmonary stents. For instance, the introduction of drug-eluting stents has shown to reduce restenosis rates significantly. In future, the global market for advanced stent technologies is expected to exceed $6 billion, indicating a robust demand for improved solutions in the APAC region, driven by better patient outcomes and lower complication rates.
• Rising Geriatric Population:The geriatric population in APAC is projected to reach 1.2 billion in future, according to the United Nations. This demographic shift is associated with an increased incidence of respiratory diseases, necessitating advanced treatment options like pulmonary stents. The growing elderly population is expected to drive healthcare spending, with estimates suggesting that healthcare costs for this demographic will rise to $1.2 trillion in the region, further boosting the demand for pulmonary stents.

Market Challenges

• High Cost of Stent Procedures:The cost of pulmonary stent procedures can be prohibitively high, often exceeding $12,000 per patient in some APAC countries. This financial burden can limit access to necessary treatments, particularly in lower-income regions. As healthcare budgets tighten, hospitals may prioritize cost-effective solutions, potentially hindering the adoption of advanced stent technologies and impacting overall market growth.
• Regulatory Hurdles:The regulatory landscape for medical devices in APAC is complex, with varying approval processes across countries. For instance, obtaining approval from the Central Drugs Standard Control Organization (CDSCO) in India can take over 14 months. These lengthy approval times can delay the introduction of innovative stent technologies, creating barriers for manufacturers and limiting patient access to the latest advancements in pulmonary care.

APAC Pulmonary Stents Market Future Outlook

The APAC pulmonary stents market is poised for significant growth, driven by technological advancements and an increasing focus on personalized medicine. As healthcare systems evolve, the integration of digital health technologies will enhance patient monitoring and treatment outcomes. Additionally, the rise of telemedicine is expected to facilitate follow-up care, improving patient adherence to treatment plans. These trends indicate a shift towards more efficient and patient-centered healthcare delivery in the region, fostering a favorable environment for market expansion.

Market Opportunities

• Expansion into Untapped Markets:Emerging economies in APAC, such as Vietnam and Bangladesh, present significant opportunities for market expansion. With increasing healthcare investments projected to reach $120 billion in future, companies can capitalize on the growing demand for pulmonary stents in these regions, addressing unmet medical needs and enhancing patient access to advanced treatments.
• Development of Biodegradable Stents:The development of biodegradable stents is gaining traction, with the global market expected to reach $1.5 billion in future. This innovation aligns with the increasing demand for minimally invasive procedures and patient-centric care, offering a sustainable alternative that reduces long-term complications and enhances recovery, thus presenting a lucrative opportunity for manufacturers in the APAC region.